MX2022006326A - Agonista del receptor de esfingosina-1-fosfato, metodo de preparacion para el mismo, y composicion farmaceutica que lo contiene como ingrediente activo. - Google Patents

Agonista del receptor de esfingosina-1-fosfato, metodo de preparacion para el mismo, y composicion farmaceutica que lo contiene como ingrediente activo.

Info

Publication number
MX2022006326A
MX2022006326A MX2022006326A MX2022006326A MX2022006326A MX 2022006326 A MX2022006326 A MX 2022006326A MX 2022006326 A MX2022006326 A MX 2022006326A MX 2022006326 A MX2022006326 A MX 2022006326A MX 2022006326 A MX2022006326 A MX 2022006326A
Authority
MX
Mexico
Prior art keywords
same
sphingosine
pharmaceutical composition
receptor agonist
phosphate receptor
Prior art date
Application number
MX2022006326A
Other languages
English (en)
Inventor
Seung Yup Paek
Deok Seong Park
Sang Yong Hong
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2022006326A publication Critical patent/MX2022006326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona a un compuesto novedoso representado por la Fórmula 1, que funciona como un agonista del receptor de esfingosina-1-fosfato útil para tratar trastornos autoinmunes, un método de preparación para el mismo, una composición farmacéutica que lo contiene como un ingrediente activo y un uso. El compuesto de acuerdo con la presente invención tiene un efecto en las enfermedades autoinmunes extensivas y enfermedades inflamatorias crónicas, que incluyen esclerosis múltiple recurrente-remitente, y también se puede utilizar para tratar o prevenir trastornos inmunoreguladores.
MX2022006326A 2019-12-03 2020-11-20 Agonista del receptor de esfingosina-1-fosfato, metodo de preparacion para el mismo, y composicion farmaceutica que lo contiene como ingrediente activo. MX2022006326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190159309 2019-12-03
PCT/KR2020/016468 WO2021112461A1 (ko) 2019-12-03 2020-11-20 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
MX2022006326A true MX2022006326A (es) 2022-06-22

Family

ID=76222576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006326A MX2022006326A (es) 2019-12-03 2020-11-20 Agonista del receptor de esfingosina-1-fosfato, metodo de preparacion para el mismo, y composicion farmaceutica que lo contiene como ingrediente activo.

Country Status (12)

Country Link
US (1) US20230047472A1 (es)
EP (1) EP4050010B1 (es)
JP (1) JP7427314B2 (es)
KR (1) KR102576671B1 (es)
CN (1) CN114761401A (es)
AU (1) AU2020397746B2 (es)
BR (1) BR112022010761A2 (es)
CA (1) CA3158593A1 (es)
ES (1) ES2964482T3 (es)
MX (1) MX2022006326A (es)
WO (1) WO2021112461A1 (es)
ZA (1) ZA202206112B (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092116A1 (en) * 2003-04-10 2004-10-28 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
EP2592066B1 (en) * 2004-12-13 2014-12-03 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medical use thereof
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
AU2007323540A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
KR20090101370A (ko) 2007-01-10 2009-09-25 알바니 몰레큘라 리써치, 인크. 5-피리디논 치환된 인다졸
PL2354134T3 (pl) * 2008-12-05 2016-07-29 Astellas Pharma Inc Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny
KR101077555B1 (ko) 2008-12-05 2011-10-28 한국전자통신연구원 무선 통신 시스템에서 ｍｉｍｏ를 이용한 데이터 송신 장치
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US9034921B2 (en) * 2011-06-01 2015-05-19 Green Cross Corporation Diphenylmethane derivatives as SGLT2 inhibitors
KR101939657B1 (ko) * 2013-02-20 2019-01-17 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물

Also Published As

Publication number Publication date
AU2020397746A1 (en) 2022-06-09
US20230047472A1 (en) 2023-02-16
KR102576671B1 (ko) 2023-09-11
ZA202206112B (en) 2023-06-28
CN114761401A (zh) 2022-07-15
CA3158593A1 (en) 2021-06-10
KR20210069567A (ko) 2021-06-11
WO2021112461A1 (ko) 2021-06-10
EP4050010A1 (en) 2022-08-31
ES2964482T3 (es) 2024-04-08
AU2020397746B2 (en) 2024-02-01
BR112022010761A2 (pt) 2022-08-23
EP4050010B1 (en) 2023-10-18
JP7427314B2 (ja) 2024-02-05
JP2023505046A (ja) 2023-02-08
EP4050010A4 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
MX2015009986A (es) Agonistas del receptor de esfingosina-1-fosfato, metodos para prepararlos y composiciones farmaceuticas que contienen los mismos como un agente activo.
CU20190045A7 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (dhodh) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios
MX2023001917A (es) Inhibidores de la fosfatasa shp2 y metodos para su uso.
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CR20210201A (es) Nuevos compuestos antihelmínticos
MX2023007192A (es) Inhibidores de prmt5.
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
MX2020009235A (es) Formulacion oftalmica.
MX2020011873A (es) Nuevos derivados de quinolina.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2022013388A (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
EP4252849A3 (en) Depot systems comprising glatiramer acetate
SG11201805791RA (en) COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α
MX2021004551A (es) Composicion farmaceutica para el tratamiento de la anemia aplasica.
MX2022006326A (es) Agonista del receptor de esfingosina-1-fosfato, metodo de preparacion para el mismo, y composicion farmaceutica que lo contiene como ingrediente activo.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2013002649A (es) Agente terapeutico contra el dolor.